Scancell Holdings (SCLP) AI Stock Analysis

• Market Cap: £121.94M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: -94.12%
• Country: UK
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 1,037,781,400
• 10 Day Avg. Volume: 991,653
• 30 Day Avg. Volume: 1,200,950
• PEG Ratio: -0.10
• Price to Book (P/B): -27.20
• Price to Sales (P/S): 22.14
• P/FCF Ratio: -17.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: 12.00p ▲(23.08% Upside)

The score is held back primarily by weak financial performance (ongoing losses, negative equity, and cash burn), only partly offset by improved burn in 2025. Technicals show an uptrend but are extremely overextended, adding pullback risk. The latest earnings call was comparatively supportive due to strengthened liquidity/runway and pipeline/regulatory progress, while valuation remains difficult to justify using traditional metrics because the company is loss-making.

Positive Factors

Strategic Partnership

The partnership with NHS enhances Scancell's strategic position by expediting access to its cancer vaccine, potentially increasing market penetration and accelerating clinical development.

Promising Clinical Data

The promising clinical data from the Phase 2 trial underscores the potential of Scancell's vaccine to transform melanoma treatment, supporting future growth and market expansion.

Management Incentives

Granting share options aligns management's interests with shareholders, potentially improving leadership stability and strategic focus, which is crucial for long-term success.

Negative Factors

Zero Revenue

The absence of revenue highlights Scancell's struggle to monetize its innovations, posing risks to financial sustainability and limiting resources for R&D and growth.

Negative Cash Flow

Persistent negative cash flow indicates insufficient cash generation from operations, threatening the company's ability to sustain itself and invest in future opportunities.

High Leverage

High leverage limits financial flexibility and increases risk, potentially hindering Scancell's ability to secure additional funding or navigate financial challenges.

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

How the Company Makes Money

Scancell Holdings makes money primarily through the development and commercialization of its immunotherapy technologies. The company's revenue model includes licensing agreements with pharmaceutical and biotechnology companies, where Scancell grants rights to develop and market its therapeutic products in exchange for upfront payments, milestone payments, and royalties on sales. Additionally, Scancell may receive funding from research grants and partnerships with academic institutions that support the advancement of its technology platforms. These collaborations and partnerships are significant contributors to the company's earnings, helping to finance ongoing research and development activities.

Scancell Holdings Financial Statement Overview

Summary

Scancell Holdings is facing severe financial challenges characterized by zero revenue, consistent losses, and a highly leveraged balance sheet. The negative cash flow situation compounds these issues, indicating that the company may struggle to sustain operations and finance future growth without significant changes or infusions of capital. Caution is advised due to the high-risk financial profile.

Income Statement

Scancell Holdings has faced significant challenges in generating revenue, with zero revenue reported in the most recent period. The company has consistently operated at a loss with a negative net income and gross profit, indicating weak profitability. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. The lack of revenue growth highlights the company's struggle to penetrate or expand its market presence.

Balance Sheet

The company's balance sheet reveals a concerning financial structure, with negative stockholders' equity indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, but high total debt relative to total assets suggests significant leverage. The equity ratio is negative, signaling that liabilities exceed assets. This poses substantial risk to financial stability and could limit future financing options.

Cash Flow

Scancell Holdings has experienced negative free cash flow, with a downward trend over the past years. The operating cash flow is negative, indicating that the company is not generating sufficient cash from operations to cover its expenses, let alone invest in growth. The free cash flow to net income ratio is not meaningful due to negative values, reflecting persistent cash flow challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.71M	4.71M	0.00	5.27M	0.00	0.00
Gross Profit	3.59M	3.59M	-966.00K	4.75M	-740.00K	-249.00K
EBITDA	-12.71M	-12.71M	-7.06M	-12.19M	-3.75M	-14.90M
Net Income	-12.27M	-12.27M	-5.86M	-11.94M	-2.06M	-15.48M
Balance Sheet
Total Assets	23.09M	23.09M	23.58M	30.27M	49.06M	8.82M
Cash, Cash Equivalents and Short-Term Investments	16.89M	16.89M	14.82M	19.92M	28.73M	41.11M
Total Debt	16.27M	16.27M	19.87M	21.13M	18.92M	15.39M
Total Liabilities	26.93M	26.93M	27.08M	36.50M	29.57M	1.17M
Stockholders Equity	-3.83M	-3.83M	-3.50M	-6.23M	18.11M	19.48M
Cash Flow
Free Cash Flow	-6.12M	-6.12M	-15.84M	-8.34M	-8.55M	-4.80M
Operating Cash Flow	-6.11M	-6.11M	-15.66M	-8.14M	-7.80M	-4.77M
Investing Cash Flow	-1.54M	-1.54M	178.00K	81.00K	-741.00K	-13.00K
Financing Cash Flow	9.73M	9.73M	10.39M	-746.00K	46.08M	46.08M

Scancell Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Positive. The current price of 9.75 is below the 20-day moving average (MA) of 10.37, below the 50-day MA of 10.02, and below the 200-day MA of 9.88, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 73.13 is Negative, neither overbought nor oversold. The STOCH value of 82.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SCLP.

Scancell Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£31.15M	-3.73	-204.29%	―	3.31%	21.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£34.79M	-4.43	-46.84%	―	―	―
SCLP	48 Neutral	£121.94M	-8.98	―	―	―	-94.12%
SAR	47 Neutral	£27.61M	-5.93	-202.14%	―	―	23.76%
4BB	41 Neutral	£91.36M	-5.94	-209.34%	―	198.49%	-26.66%
OBI	37 Underperform	£41.47M	-2.02	―	―	63.25%	8.94%

Scancell Holdings Corporate Events

Scancell’s iSCIB1+ Shows Promising Results in Melanoma Trial

Scancell Holdings has announced positive updated data from its SCOPE Phase 2 trial, demonstrating that its iSCIB1+ therapy, in combination with standard checkpoint inhibitors, significantly improves progression-free survival (PFS) in patients with advanced melanoma. The PFS rate of 74% at 16 months surpasses the standard of care’s 50% at 11.5 months, and early overall survival data shows a 14% improvement. These results support further development of iSCIB1+ for late-stage trials, with regulatory feedback aligning on trial design and endpoints. The announcement positions Scancell favorably in the immunotherapy market, potentially redefining the standard of care for melanoma and enhancing patient outcomes.

Scancell’s iSCIB1+ Shows Promising Results in Melanoma Treatment

Scancell Holdings announced positive Phase 2 trial results for their iSCIB1+ Immunobody® DNA active immunotherapy in treating late-stage melanoma, presented at the SITC 2025 meeting. The trial showed a progression-free survival rate of 78% at 11 months, significantly higher than the historical 46% with existing therapies, positioning iSCIB1+ as a transformative treatment option. The company plans to accelerate development, including regulatory discussions and randomized studies set to begin in 2026, potentially expanding treatment to 80% of late-stage melanoma patients.

Scancell Holdings Successfully Passes AGM Resolutions

Scancell Holdings announced that all resolutions at their Annual General Meeting were passed, marking a positive step for the company. This development supports Scancell’s ongoing efforts in advancing their immunotherapy platforms, which could enhance their position in the biotechnology industry and benefit stakeholders by potentially offering innovative cancer treatments.